In PhIII data, Eli Lilly’s Retevmo meets primary endpoint of improving progression-free survival

Eli Lil­ly’s Retev­mo to treat ad­vanced or metasta­t­ic re­arranged dur­ing trans­fec­tion (RET)-mu­tant medullary thy­roid can­cer (MTC) showed promis­ing re­sults at im­prov­ing pro­gres­sion-free sur­vival com­pared to mul­ti­k­i­nase in­hibitors, in topline da­ta the com­pa­ny re­leased Tues­day.

The LI­BRET­TO-531 tri­al met its pri­ma­ry end­point, show­ing a sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment in pro­gres­sion-free sur­vival, Eli Lil­ly said in a press re­lease. The ran­dom­ized Phase III study sought to com­pare Retev­mo to the mul­ti­k­i­nase in­hibitors cabozan­ti­nib or van­de­tanib.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.